Valuation: Navana Pharmaceuticals PLC

Market Cap 7.74B 61.95M 56.14M 51.93M 46.85M 88.29M 5.84B 91.41M 624M 247M 3.12B 232M 228M 9.9B P/E 2024
23.2x
P/E 2025 11.1x
Enterprise Value 12.17B 97.39M 88.25M 81.63M 73.65M 139M 9.18B 144M 981M 389M 4.91B 365M 358M 15.57B EV / Sales 2024
2.09x
EV / Sales 2025 1.11x
Free-Float
68.17%
Yield 2024
1.6%
Yield 2025 2.78%
1 day-0.63%
1 week+4.30%
Current month+6.24%
1 month+1.94%
3 months-9.22%
6 months+1.94%
Current year+21.39%
1 week 62.7
Extreme 62.70000000
65.5
1 month 57.9
Extreme 57.9
65.5
Current year 50.7
Extreme 50.7
78
1 year 48
Extreme 48
78
3 years 36.2
Extreme 36.2
118.9
5 years 26.4
Extreme 26.4
132
10 years 26.4
Extreme 26.4
132
Manager TitleAgeSince
Chief Executive Officer 65 2020-11-24
Director of Finance/CFO - 2024-06-30
Chief Tech/Sci/R&D Officer 41 2020-11-14
Director TitleAgeSince
Chairman - 2025-04-14
Director/Board Member 65 2020-11-24
Director/Board Member 56 2020-11-24
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%+4.30%+34.04%-24.46% 54.13M
+1.14%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
+0.80%+1.70%+42.03%+72.22% 386B
+0.55%+0.70%+59.02%+45.79% 364B
+1.06%+1.45%+28.00%+62.68% 302B
+0.28%-0.33%+3.15%+37.91% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.45%+1.81%+35.26%+74.04% 429B
Weighted average by Cap. +0.64%+3.26%+37.71%+99.60%

Financials

2024 2025
Net sales 6.9B 55.18M 50.01M 46.25M 41.73M 78.64M 5.2B 81.41M 556M 220M 2.78B 207M 203M 8.82B 8.84B 70.74M 64.1M 59.29M 53.5M 101M 6.67B 104M 712M 282M 3.56B 265M 260M 11.31B
Net income 405M 3.24M 2.93M 2.71M 2.45M 4.61M 305M 4.78M 32.59M 12.92M 163M 12.15M 11.89M 517M 488M 3.9M 3.54M 3.27M 2.95M 5.56M 368M 5.76M 39.29M 15.58M 197M 14.64M 14.33M 624M
Net Debt 5.03B 40.25M 36.48M 33.74M 30.44M 57.37M 3.8B 59.39M 405M 161M 2.03B 151M 148M 6.44B 4.43B 35.44M 32.11M 29.7M 26.8M 50.5M 3.34B 52.28M 357M 141M 1.78B 133M 130M 5.67B
Projected Income Statement - Annual - Navana Pharmaceuticals PLC
Logo Navana Pharmaceuticals PLC
Navana Pharmaceuticals PLC., formerly Navana Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. It operates in two segments: Human Health and Veterinary. The Human Health segment is engaged in manufacturing marketing and selling of pharmaceutical products. It produces tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, eye drops, creams, ointments, and others. The Veterinary segment is engaged in manufacturing marketing distributing and selling of veterinary, poultry and fisheries products. The Company's products include Pmec, Stenide Cream, Agonil Cream, Vontac Tablet, Floxacin, Inpen, Osmina, Methebac, Kcit, Ezitor, Droniva, Ospemifene, Ferri Maltol, Lvofloxacin, Nafgal, Esona, Clonipres, Meltix, Diplin, and Arokast, among others.
Employees
4,798
Date Price Change Volume
26-11-15 BDT 63.00 -0.63% 398,648
26-11-12 BDT 63.40 -0.78% 213,516
26-11-11 BDT 63.90 -1.54% 424,632
26-11-10 BDT 64.90 +2.37% 520,085
26-11-09 BDT 63.40 +4.97% 597,936
  1. Stock Market
  2. Stocks
  3. NAVANAPHAR Stock